Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Arvinas, Inc. (N

Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC pla

Evercore ISI Group analyst Jonathan Miller maintains Arvinas (NASDAQ:ARVN) with a Outperform and

Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the pri

Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about

Arvinas (NASDAQ: ARVN) said it is concentrating resources on its early-stage oncology and neurology

Wells Fargo analyst Derek Archila downgrades Arvinas (NASDAQ:ARVN) from Overweight to Equal-Weigh

Wedbush analyst Robert Driscoll maintains Arvinas (NASDAQ:ARVN) with a Neutral and raises the pri

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pi

Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensu

Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the

Arvinas (NASDAQ:ARVN) reported quarterly earnings of $2.58 per share which beat the analyst consensu

– Secured the first-ever regulatory approval of a PROTAC (a type of  heterobifunctional protein degr

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology co

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat

Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted

Stephens & Co. analyst Sudan Loganathan reiterates Arvinas (NASDAQ:ARVN) with a Overweight an

Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its

NEW HAVEN, Conn. , May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage b

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage bi

Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Phar

Barclays analyst Etzer Darout maintains Arvinas (NASDAQ:ARVN) with a Overweight and raises the pr

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including

BTIG analyst Jeet Mukherjee maintains Arvinas (NASDAQ:ARVN) with a Buy and raises the price targ

Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is enteri

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer fol

Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensi

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Est

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's

Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted

Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.90) per share which missed the analyst consen

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline

Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment fo

Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:ARVN) with a Buy and raises the pri

Arvinas, Inc. (NASDAQ:ARVN), today with its partner Pfizer Inc. (NYSE:PFE), announced that the U.S.